Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

Mostrar otras versiones (1)

Vaccines and drugs have helped reduce disease severity and blunt the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting t...

Descripción completa

Detalles Bibliográficos
Autores principales: Moghadasi, Seyed Arad, Heilmann, Emmanuel, Khalil, Ahmed Magdy, Nnabuife, Christina, Kearns, Fiona L., Ye, Chengjin, Moraes, Sofia N., Costacurta, Francesco, Esler, Morgan A., Aihara, Hideki, von Laer, Dorothee, Martinez-Sobrido, Luis, Palzkill, Timothy, Amaro, Rommie E., Harris, Reuben S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058310/
https://www.ncbi.nlm.nih.gov/pubmed/36989354
http://dx.doi.org/10.1126/sciadv.ade8778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058310/
https://www.ncbi.nlm.nih.gov/pubmed/36989354
http://dx.doi.org/10.1126/sciadv.ade8778

Ejemplares similares